ReviewAdvances in experimental medicine and biology2026
Glucose and Lactate, Starters or Intermediates of Cancer Metabolic Rewiring.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cells undergo extensive metabolic reprogramming to sustain rapid proliferation and adapt to the hostile conditions of the tumor microenvironment. Central to this metabolic shift are glucose and lactate, which serve not only as essential energy substrates but also as potent signaling molecules that influence tumor growth, survival, and progression. This chapter explores the molecular mechanisms underlying enhanced glucose uptake and glycolytic metabolism in cancer cells, with a focus on their roles in supporting anabolic biosynthesis, promoting immune evasion, and activating key oncogenic signaling pathways, including HIF-1α, c-Myc, and the PI3K/Akt/mTOR axis. Furthermore, it delves into the evolving perception of lactate, not as a mere metabolic waste product, but as a dynamic fuel source, a modulator of tumor microenvironmental heterogeneity, and a driver of therapeutic resistance. By unraveling the complex interplay between glucose and lactate metabolism, this chapter provides deeper insight into the metabolic architecture of cancer and presents emerging strategies to target these vulnerabilities for more effective and personalized cancer therapies.
Indexed as
Identifiers
42435166What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.